Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-4508 + SHR-A1811
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
HRS-4508 + SHR-A1811 is a combination therapy under clinical investigation for the treatment of advanced solid tumors, including non-small cell lung cancer and breast cancer. - **HRS-4508** is a small-molecule inhibitor developed by Jiangsu Hengrui Medicine and is currently in phase 2 clinical development for solid tumors and non-small cell lung cancer[2][5][8]. - **SHR-A1811** is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), composed of a trastuzumab-derived antibody, a cleavable linker, and a topoisomerase I inhibitor payload[1][3][4]. It demonstrates antitumor activity in HER2-expressing or HER2-mutated cancers, including breast cancer and non-small cell lung cancer[1][3][4][10]. The combination is being evaluated in clinical trials for synergistic antitumor activity, particularly in HER2-expressing advanced solid tumors[7][10].
- Other names
- trastuzumab rezetecan
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HRS-4508 + SHR-A1811.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-4508 + SHR-A1811.